Nachrichten zur Episurf Medical AB Aktie

Niles Noblitt, through Sacajo Investments LLC, makes investment in Episurf through an arrangement with CEO Pål Ryfors

In order to facilitate settlement of an acquisition of 9,526,170 Class B shares in Episurf Medical AB (publ) (“Episurf” or…

Episurf Medical to present at Pareto Securities Healthcare Conference on September 19, 2024

Episurf Medical (Nasdaq: EPIS B) to present at Pareto Securities Healthcare Conference on September 19, 2024. The event is arranged…

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B) has, pursuant to previously announced information, carried out a rights issue of units consisting…

Episurf Medical resolves on an issue of units to guarantors in connection with the completed rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

Episurf Medical announces outcome of the rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

Episurf Medical to present at Redeye Growth Day today, May 30[th], 2024

Episurf Medical (Nasdaq: EPIS B) will present at Redeye Growth Day today, May 30th, 2024. The event is arranged by…

Episurf Medical publishes prospectus in connection with the company’s partially guaranteed rights issue of up to approximately SEK 120 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

SUMMARY FROM THE EXTRAORDINARY GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

Episurf Medical AB (publ) held an Extraordinary General Meeting in Stockholm today 22 May 2024 at which it was resolved,…

DNB Markets – Episurf Medical: New US distributor agreement

Episurf Medical reported Q1 earnings (loss) broadly in line with our expectation, despite somewhat lower sales. While it seems to…

Notice of Extraordinary General Meeting of Episurf Medical AB (publ)

The shareholders of Episurf Medical AB (publ), reg. no. 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Extraordinary…

Episurf Medical announces a partially secured rights issue of units of up to approximately SEK 120 million

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

SUMMARY FROM ANNUAL GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

Episurf Medical AB (publ) (“Episurf” or the “Company”) held its Annual General Meeting (the “Meeting”) on Tuesday, 9 April 2024…

Episurf Medical AB’s 2023 annual report is now available

Episurf Medical’s annual report for 2023 is available as of today at the company’s website, www.episurf.com. Episurf Medical has of environmental and…

Episurf Medical to present at Life Sciencedagen on March 6, 2024

Episurf Medical (Nasdaq: EPIS B) will attend Life Sciencedagen which is held on March 6, 2024. The company will be…

Notice of Annual General Meeting of Episurf Medical AB (publ)

This English translation of the notice is an unofficial translation of the Swedish original. In case of any discrepancies between…

Nomination Committee’s proposal regarding board of directors of Episurf Medical AB for 2024

Episurf Medical’s Nomination Committee proposes six regular board members without deputies, including the re-election of Ulf Grunander as chairman of…

DNB Markets – Episurf Medical: Sales moving in the right direction

Q4 sales were in line with our forecast, but operating expenses were higher. Overall, we believe sales growth will be…

Results from up to 10 years follow-up of Episealer® patients accepted for presentation at international orthopaedic congress

Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Survivorship and clinical outcome of a novel personalized metal implant…

Episurf Medical to present at Redeye Life Science Day on November 23rd, 2023

Episurf Medical (Nasdaq: EPIS B) will attend Redeye Life Science Day which is held on November 23rd, 2023. The event…

Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2024

In accordance with the decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The…

Episurf Medical to present at Pareto Securities Healthcare Conference on September 14, 2023

Episurf Medical (Nasdaq: EPIS B) will present at Pareto Securities Healthcare Conference on September 14, 2023. The event is arranged…

Episurf Medical: First commercial case in the US scheduled

Episurf Medical (Nasdaq: EPIS B) today announces that the companys first commercial case in the US has been scheduled for…

Episurf Medical: Strategy update to take the next commercial steps and improve financial results

Episurf Medical (Nasdaq: EPIS B) today announces that the company is implementing a strategic focus that brings an increased focus…

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B): During June, shareholders exercised 153,527 warrants (TO4B). The number of shares has increased by…

Correction of previously communicated press release

Press release 30 June 2023 14:50 CEST Correction of previously communicated press release Episurf Medical AB (publ) ("Episurf") announces correction in relation to…

Episealer® Patellofemoral System available in United Arab Emirates

Episurf Medical (NASDAQ: EPIS B) today announces that the Ministry of Health & Prevention in the United Arab Emirates has…

Episurf Medical to present at Redeye Growth Day today, June 1st, 2023

Episurf Medical (Nasdaq: EPIS B) will present at Redeye Growth Day today, June 1st, 2023. The event is arranged by…

SUMMARY FROM ANNUAL GENERAL MEETING OF EPISURF MEDICAL AB (PUBL)

Episurf Medical AB (publ) (“Episurf” or the “Company”) held its Annual General Meeting (the “Meeting”) on Thursday, 4 May 2023…

Episurf Medical provides update on establishment of US commercial organisation

Episurf Medical (Nasdaq: EPIS B) today provides an update on the establishment of a US commercial organisation. In line with…

New Canadian patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Canadian Intellectual Property Office (CIPO). The patent,…

Notice of Annual General Meeting of Episurf Medical AB (publ)

This English translation of the notice is an unofficial translation of the Swedish original. In case of any discrepancies between…

Episurf Medical to present at Innovative Orthopedics hosted by Redeye on March 21st, 2023

Episurf Medical (Nasdaq: EPIS B) will present at Innovative Orthopedics on March 21st, 2023. The event is arranged by Redeye…

First Episealer® surgery in Malaysia scheduled

Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery in Malaysia with the knee implant Episealer® has been…

Episurf Medical to present at Stockholm Corporate Finance Life Science Capital Markets Day on March 8th, 2023

Episurf Medical (Nasdaq: EPIS B) will attend Stockholm Corporate Finance Life Science Capital Markets Day on March 8th, 2023. The…

New Indian patent approval for Episurf Medical

The Indian patent office Intellectual Property India has reported that Episurf Medical (NASDAQ: EPIS B) has received another granted patent…

New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO).…

Episealer® health economy publication accepted for publication in Journal of ISAKOS

Episurf Medical (Nasdaq: EPIS B) today announces that results from a cost utility study, focusing on the health economic aspects…

Information from the Nomination Committee of Episurf Medical

Episurf Medical (Nasdaq: EPIS B) today announces that the Chairman of the Board of Directors, Dennis Stripe, has informed the…

New US patent approval for Episurf Medical

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO).…

Change in number of shares and votes in Episurf Medical

Episurf Medical AB (NASDAQ: EPIS B): During December, shareholders exercised 256,877 warrants (TO4B). The number of shares has increased by…

Episurf Medical receives FDA 510(k) clearance for Episealer® Patellofemoral System

Episurf Medical (NASDAQ: EPIS B) today announces that the company has received 510(k) clearance from the US Food and Drug…

Episealer® Knee technology to be presented at European scientific congress

Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee technology will be presented at the ESSKA Speciality Days…

Episurf Medical reaches important regulatory milestone in India

Episurf Medical (Nasdaq: EPIS B) today announces that the Indian authorities have, through their Directorate General of Health Services, Central…

Episurf Medical furthers MTP implant preparations by adding Dr. Thomas Roukis, D.P.M., Ph.D. to its Lower Extremity Specialist group

Episurf Medical (Nasdaq: EPIS B) today announces that as it continues development of its MTP implant, the company has added…

dpa-AFX ProFeed